Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »
Sep 19, 2013

Stem Cells in the EU: Northern and Central Markets

Learn about stem cell institutions and opportunities in the U.K., Germany, the Netherlands, Belgium, and Sweden in this incisive report.

Stem Cells in the EU: Northern and Central Markets

The markets of northern and central Europe are ones to watch. [© beugdesign - Fotolia.com]

  • The focus of this GEN Market & Tech Analysis Report is to present some characteristics of selected Northern/Central EU markets vis-à-vis institutions, funding/opportunities in the broader stem cells field [and focusing as appropriate on stem cell banking, iPSCs, cord blood]. We present here data collected by our U.K. research team via primary market research from across Europe focusing on the following countries:

    • U.K.
    • Germany
    • The Netherlands
    • Belgium
    • Sweden

    Taken together, these data frame some of the characteristics, institutions as well as stem cell research opportunities in these countries. In a future GENReport, we will provide an analysis of the regulatory landscape in selected EU countries.

    CLICK HERE to download the PDF report.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »